Posted on 1/20/21
Here's Why Bristol Myers Squibb's Partners Think 2021 Could Be Prosperous
In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss upcoming . . .
Posted on 1/20/21
Where Will Pfizer Be in 5 Years?
Investors threw piles of money at up-and-coming biotechs last year, and that was before the coronavirus pandemic accelerated the trend even further. This capital isn't taking . . .
Posted on 1/19/21
Ortho Clinical Diagnostics Launch of IPO
Ortho Clinical Diagnostics Holdings plc, the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, . . .
Posted on 1/19/21
Signet Healthcare and Bionpharma Sell CoreRx
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Signet Healthcare Partners and Bionpharma Inc today announced the sale of CoreRx, a global contract development and manufacturing . . .
Posted on 1/19/21
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty . . .
Posted on 1/19/21
Better Choice Company Closes Strategic Investment of $2.7 Million
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Better Choice Company (OTCQX: BTTR) (“Better Choice”), an animal health and wellness company, today announced the closing of . . .
Posted on 1/19/21
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma
Posted on 1/19/21
Can the Pfizer and Moderna Vaccines Beat the New Coronavirus Strains?
Investors in Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) may have breathed a sigh of relief when the U.S. Food and Drug Administration granted the companies' coronavirus vaccines . . .
Posted on 1/19/21
Is Pfizer Stock a Buy?
Let me get cut to the chase: Yes, I think Pfizer (NYSE:PFE) stock is a buy. And yes, I realize that could be surprising considering that . . .
Posted on 1/19/21
Should You Buy Johnson & Johnson For Its COVID Vaccine?
So far, some coronavirus vaccine stocks have offered investors enormous gains in a short period of time. For example, Moderna (NASDAQ:MRNA) stock climbed more than 400% . . .
Posted on 1/19/21
ProPhase Labs Prices of Public Offering of Common Stock
GARDEN CITY, NY, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today the pricing of . . .
Posted on 1/16/21
ProPhase Labs Proposes Public Offering of Common Stock
GARDEN CITY, NY, Jan. 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has . . .
Posted on 1/15/21
Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project
Genetic testing expert Invitae (NYSE:NVTA) has received the backing of some of the largest pharmaceutical companies in the industry. Bristol Myers Squibb (NYSE:BMY), Johnson & Johnson . . .
Posted on 1/15/21
Could Regeneron Pharmaceuticals Be a Millionaire-Maker Stock?
If you had invested $10,000 during Regeneron Pharmaceuticals' (NASDAQ:REGN) inception in the 1990s, that investment would have turned into more than $317,000 as of Jan. 11, . . .
Posted on 1/14/21
KidsX Selects 13 Startups for Inaugural Cohort
LOS ANGELES--(BUSINESS WIRE)--KidsX, an international consortium of pediatric hospitals focused on improving digital health innovation through collaboration, has selected 13 startup companies to be part of . . .
Posted on 1/14/21
Provention Bio Prices $100M Public Offering of Common Stock
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering . . .
Posted on 1/13/21
Applied DNA Closes of $15 Million Registered Direct Offering
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced . . .
Posted on 1/13/21
Columbia Care Closes of Public Offering
NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) is pleased to announce that it has closed its previously announced bought deal . . .
Posted on 1/12/21
Rose Health Announces Oversubscribed Seed Round
Rose Health, a Baltimore-based mental health technology startup recently named one of the DC area’s 21 startups to watch, announced the conclusion of its oversubscribed seed . . .
Posted on 1/12/21
Solaris Health Partners With MidLantic Urology Partners
NEW YORK--(BUSINESS WIRE)--Solaris Health, a partnership formed by New York-based Integrated Medical Professionals and Cincinnati-based The Urology Group, has joined forces with The Centers for Advanced Urology, . . .
Posted on 1/12/21
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock
CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, today announced it has entered into a securities . . .
Posted on 1/12/21
Better Choice Secures $12.0 Million Credit Facility
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Better Choice Company (OTCQX: BTTR) , an animal health and wellness company is proud to announce it has . . .
Posted on 1/12/21
Antares Pharma Announces Full-Year 2021 Revenue Guidance of $175-200 Million
EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue . . .
Posted on 1/12/21
electroCore Provides Business Update and Select Financial Guidance
BASKING RIDGE, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as . . .
Posted on 1/12/21
Amneal to Acquire Kashiv Specialty Pharmaceuticals
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX) and Kashiv BioSciences LLC today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC, a wholly-owned subsidiary of . . .
New York
